Welcome to our dedicated page for ChromaDex Corporation news (Ticker: $CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ChromaDex Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ChromaDex Corporation's position in the market.
Rhea-AI Summary
Neurohacker Collective has launched Qualia NAD+ featuring ChromaDex's patented Nicotinamide Riboside (NR) as an NAD+ supplement to boost NAD+ levels in aging Americans. The pilot study resulted in 95% of participants rating the experience as 'excellent' to 'good.' Qualia NAD+ is positioned to become a category leader in NAD+ supplementation, leveraging Niagen, the FDA-notified form of NR, backed by two Nobel Prize winners and over 25 human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) shares results from a new study on the safety and benefits of high-dose nicotinamide riboside (NR) supplementation for individuals with Parkinson’s disease. The study demonstrated that supplementing individuals with PD with high-dose Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, and was associated with a significant clinical improvement. This marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the results of a phase II clinical study on Niagen NR, demonstrating up to fourfold increase in NAD+ levels, improved coordination and eye movement in Ataxia Telangiectasia (AT) patients. The study is the longest Niagen NR clinical trial to date, spanning two years, and showcases that long-term Niagen NR is safe and well tolerated. The promising results highlight the potential of Niagen NR in supporting brain health and cognition, indicating a potential therapeutic strategy for AT patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
Rhea-AI Summary
ChromaDex Corporation (NASDAQ: CDXC) to Participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ: CDXC) announced third-quarter 2023 financial results, including $19.5 million in net sales, a 61.4% gross margin, and a $1.0 million net loss. Key highlights are Tru Niagen® sales growth and a positive Adjusted EBITDA of $0.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
-
Rhea-AI Summary
ChromaDex Corp. launches Tru Niagen Pro 1,000mg, a clinical strength supplement proven to boost NAD+ levels by up to 150% in as little as three weeks. The product features 1,000mg of Niagen, a superior quality NAD+ precursor. It is recommended by physicians and used by pro-athletes. Tru Niagen Pro 1,000mg is Certified for Sport® by NSF International.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 8, 2023, at 4:30 p.m. ET to discuss its financial results for the third quarter of 2023. The results will be reported in a press release after the close of regular stock market trading hours on the same day. The conference call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ChromaDex and Zesty Paws launch Healthy Aging NAD+ Precursor supplement for dogs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
-
Rhea-AI Summary
ChromaDex Corp shares results from a clinical study showing that supplementation with nicotinamide riboside (NR) reduces inflammation in healthy subjects and psoriasis patients. NR is proven to increase NAD+ levels safely and effectively. This research supports the anti-inflammatory effects of NR in both healthy individuals and those with inflammation-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ChromaDex Corp. shares findings from a preclinical study on NMN and NR, indicating that NR is a more efficient NAD+ precursor than NMN. NMN cannot cross the cell membrane directly and must first be converted to NR. NR was 25% more effective in raising whole blood NAD+ levels compared to NMN in a clinical study. NMN's phosphate group prevents it from entering the cell directly, while NR can be directly imported into human cells. The U.S. FDA's decision to disallow NMN as a dietary supplement does not affect NR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
ChromaDex Corporation
Nasdaq:CDXC
CDXC Rankings
CDXC Stock Data
285.48M
51.40M
41.19%
16.13%
1.75%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
LOS ANGELES
About CDXC
chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).